Recommendations for Prehospital Dosing Schedule of Naloxone

705 Words2 Pages

Recommendations for Prehospital Dosing Schedule of Naloxone
Naloxone is a potent antagonist of the binding of opioids to their receptor sites within the brain and spinal cord. Administration of naloxone will reverse the central nervous system and respiratory depression resulting from an opioid overdose (Soar et al., 2005; Soar et al., 2010; Van Hoek et al., 2010). Naloxone has a long established use in prehospital emergency resuscitation of patients with narcotic overdose, and with very little pharmacological effect otherwise, the drug is evidenced to possess very little, if any, negative effect on patient outcomes, particularly in opiate-naive patients (Albertson, 2001; Dollery, 1991; Soar et al., 2005; Soar et al., 2010; Yealy, 1990).
Although naloxone has proven to be effective within the prehospital arena, there is some concern as to the acceptable maximum cumulative dose that one person ought to receive, particularly when suffering cardiac arrest. This literature review aims to address this question and promote evidence-based prehospital guidelines.
Naloxone Dosing in the Patient Presenting with Altered Mental Status
According to the manufacturer, the Food and Drug Administration, and the American Heart Association (AHA), the suggested dosing regimen for naloxone in treating patients with an overdose of opiates is 0.4 to 2.0 mg IV, IM, SC, or IN, repeated every two to three minutes as needed up to a maximum cumulative dose of 10 mg (sometimes required for large or atypical opioid intake) at which time the suspicion of primary narcotic overdose ought to be questioned as the condition may be caused by a drug or disease process that is not responsive to naloxone (Albertson, 2001; DynaMed, 2008; Endo Pharmaceuticals, 2003; “Naloxone,” 2011; Soar et al., 2005; Soar et al., 2010; Van Hoek et al., 2010). Marraffa, Cohen, and Howland (2012) reiterates this cumulative maximum dose while advocating for lower initial dosing:

Efficacy of Naloxone in Opiate-induced Cardiac Arrest
According to the latest AHA guidelines, “naloxone has no role in the management of cardiac arrest” (Van Hoek et al., 2010, “Opioid Toxicity”). This statement, however, is in direct conflict with the AHA's "H's & T's" premise of addressing underlying causes of cardiac arrest, with one of those T's being toxicological in nature and requiring the particular antidote (in this case, naloxone) to aid in the resuscitative effort. As previously mentioned, the AHA guidelines do provide that, when naloxone is indicated, aggressive dosing may be required to reverse intoxication with atypical opioids or following a considerable overdose.

More about Recommendations for Prehospital Dosing Schedule of Naloxone

Open Document